We are monitoring the impact of COVID-19 on Europe Influenza Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1623
Share on
Share on

Europe Influenza Market Research Report – Segmented By Product Type, Consumer and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis, Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1623
Pages: 140

EU Influenza Market Size (2021 to 2026)

The Europe Influenza Market size is expected to reach USD 2.19 billion by 2026 from USD 1.39 billion in 2021, growing at a CAGR of 9.52% during the forecast period.

Key factors attributing to the growth of the European influenza market include the increasing prevalence of influenza, the government's focus on immunization programs, awareness about the disease and its prevention, and advancements in the healthcare sector with improving vaccination rates. The influenza vaccination rate among medical facilities workers in England was recorded to be around 77%. This is the highest success rate for vaccination achieved. Seasonal influenza infects about 10%-30% of the European population each year. In Germany, the incidence of seasonal influenza varies from year to year and is highest is seen in infants and children 2 to 5 years old.

Over the past several years, the complications related to influenza have increased, resulting in a growth death rate. In 2018, the number of deaths from influenza in Spain had recorded over 1,850 deaths. The World Health Organization and the Centers for Disease Control and Prevention recommend annual vaccination for almost everyone over six months, especially those at high risk. The European Center for Disease Prevention and Control also recommends annual vaccination for pregnant women, the elderly, children six months to five years old, and those with certain health problems.

The presence of favorable government policies related to influenza prevention and treatment also supports the market's growth trajectory. Furthermore, in emerging markets, the influenza market is anticipated to benefit from the increasing medical tourism and growth of immigrations during the forecast period.

The European healthcare sector is affected by growing expenses, and this reflects in the studied market. The economic burden per case is more significant in infants with over € 250 and elderly with over € 130. The burden of influenza is most remarkable among infants and young children, overburdening the regional governments.  Moreover, research and development of a new vaccine is a considerable process, with limitations of safety and effectiveness. Even the regulatory requirements and regional authorities have a complicated timeline, limiting the growth of the European influenza market.

This research report on the European Influenza Market has been segmented and sub-segmented into the following categories:

By Product Type:

  • Vaccines
  • Drugs

By Type:

  • Safety Biomarkers
  • Efficacy Biomarkers            
  • Validation Biomarkers

By Application:

  • Diagnostics Development
  • Drug Discovery and Development
  • Personalized Medicine     
  • Disease Risk Assessment 
  • Other Applications   

By Disease Indications:

  • Cancer     
  • Cardiovascular Disorders   
  • Neurological Disorders      
  • Immunological Disorders 
  • Other Diseases     

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The UK influenza market is geographically the most attractive regional market. It is anticipated to grow at a CAGR of 4.2%, aiming to reach approximately USD 445 million by the end of the forecast period. Factors such as government initiatives, the emergence of new vaccines, disposable income, well-developed infrastructure, and technological advancements for vaccine delivery will drive the market. In the UK, the Universal Childhood Influenza Vaccination Program was launched in 2018 with a live attenuated influenza vaccine. The program has been offered to 2- and 3-year-olds across the UK. Additionally, vaccination has been carried out for children at primary schools in Scotland and some parts of Ireland. These favorable initiatives indicate considerable growth in the UK influenza vaccine market over the forecast period.

Germany was the second-largest influenza market in 2020 and is anticipated to grow at a CAGR of 3.9% by 2026. France is expected to be the third-largest regional market, followed by Italy at the end of the scheduled period. In Italy, people at risk of contracting the virus, such as children, pregnant women, health workers, and the elderly, must be vaccinated. Additional factors such as reimbursement policies and a large population are likely to favor the adoption of the vaccines and medications, thus contributing to the growth of the European influenza market.

KEY MARKET PLAYERS:

Companies playing a pivotal role in the European Influenza Market are Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan) and CSL Limited (Australia).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)     

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product Type                             

                                5.1.1 Introduction           

                                5.1.2 Vaccines   

                                5.1.3 Drugs         

                                5.1.4  Y-o-Y Growth Analysis, By Product              

                                5.1.5  Market Attractiveness Analysis, By Product            

                                5.1.6  Market Share Analysis, By Product              

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Safety Biomarkers

                                5.2.3 Efficacy Biomarkers             

                                5.2.4 Validation Biomarkers        

                                5.2.5  Y-o-Y Growth Analysis, By Type    

                                5.2.6  Market Attractiveness Analysis, By Type  

                                5.2.7  Market Share Analysis, By Type    

                5.3 Application                 

                                5.3.1 Introduction           

                                5.3.2 Diagnostics Development 

                                5.3.3 Drug Discovery and Development

                                5.3.4 Personalised Medicine      

                                5.3.5 Disease Risk Assessment  

                                5.3.6 Other Applications               

                                5.3.7  Y-o-Y Growth Analysis, By Application        

                                5.3.8  Market Attractiveness Analysis, By Application      

                                5.3.9  Market Share Analysis, By Application       

                5.4 Disease Indications                 

                                5.4.1 Introduction           

                                5.4.2 Cancer      

                                5.4.3 CardiovascularDisorders    

                                5.4.4 Neurological Disorders       

                                5.4.5 Immunological Disorders  

                                5.4.6 Other Diseases      

                                5.4.7  Y-o-Y Growth Analysis, By Disease Indications        

                                5.4.8  Market Attractiveness Analysis, By Disease Indications      

                                5.4.9  Market Share Analysis, By Disease Indications       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Type

                                                6.1.3.4 By Application

                                                6.1.3.5 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Type

                                                6.1.4.4 By Application

                                                6.1.4.5 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Type

                                                6.1.5.4 By Application

                                                6.1.5.5 By Indication

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Sanofi-Pasteur                          

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca                               

                8.3 F. Hoffmann-La Roche                           

                8.4 Novartis                       

                8.5 GlaxoSmithKline                       

                8.6 Pfizer Inc.                    

                8.7 Merck & Co.                               

                8.8 Abbott Laboratories                               

                8.9 Mitsubishi Tanabe Pharma Corporation                         

                8.10 CSL Limited                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  2. Europe Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)
  5. Europe Children Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Adults Market, By Region, From 2021 to 2026 (USD Billion)
  7. U.K. Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  8. U.K. Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)
  9. Germany Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  10. Germany Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)
  11. France Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  12. France Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)
  13. Italy Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  14. Italy Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)
  15. Spain Influenza Market, By Product Type, From 2021 to 2026 (USD Billion)
  16. Spain Influenza Market, By Consumer, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample